Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MEDIGEN VACCINE BIOLOGICS CORPORATION

(6547)
  Report
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Qps, Collaborates with Medigen Vaccine Biologics Corporation to Complete Toxicology Studies Necessary for the Development of A Covid-19 Vaccine

07/30/2021 | 07:51am EDT

QPS, collaborated with Medigen Vaccine Biologics Corporation to complete toxicology studies necessary for the development of a COVID-19 vaccine. Researchers at the Center of Toxicology and Preclinical Sciences (CTPS) at QPS Taiwan completed the studies swiftly to accelerate the development of the vaccine, which has just been approved by the Taiwan Food and Drug Administration (TFDA) for Emergency Use Authorization (EUA) in Taiwan. Medigen Vaccine Biologics Corporation also successfully secured a first-of-its-kind government grant for the clinical trial of the novel vaccine, which helped expedite the vaccine development. CTPS at QPS Taiwan was the primary testing facility for the toxicity study of the novel vaccine. The researchers accepted the first clinical cases in October 2020 and completed the studies in just a few months. The team met all scientific objectives, analyzed all endpoints, and reported all outcomes as scheduled. . The team of researchers at CTPS at QPS Taiwan listened to the needs of its partner, delivering prompt and flexible study execution, frequent and thorough reporting, and on-the-fly responses to inquiries and requests. Keeping in mind optimal toxicity study designs and addressing specific requirements and concerns of the regulatory review, the researchers generated weekly updates of the ongoing study. These updates kept the client and the regulatory review abreast of the latest study advancements and outcomes. Despite the rapid pace of research, the quality of these interim reports remained consistent with the team's usual high standard for study reporting. QPS Taiwan was able to provide further support to the vaccine development effort through the QPS Unitix division. QPS Unitix deployed a legion of study nurses across four medical centers to recruit over 50 percent of the eligible subjects required for the trial in just two months.


© S&P Capital IQ 2021
All news about MEDIGEN VACCINE BIOLOGICS CORPORATION
09/07Vaccine makers should supply shots for trials to help spur sector -CEPI
RE
09/01Helped by TSMC and Foxconn, BioNTech vaccines finally reach Taiwan
RE
09/01Helped by tech giants, BioNTech vaccines finally reach Taiwan
RE
08/30Foxconn founder asks BioNTech to reserve 30 million more vaccines for Taiwan
RE
08/25REFILE-Taiwan to get BioNTech shots early as China delays approval-source
RE
08/23DYNAVAX TECHNOLOGIES : Medigen Vaccine Biologics Launch COVID-19 Vaccine in Taiw..
MT
08/22MEDIGEN VACCINE BIOLOGICS : Taiwan leader gets local COVID-19 vaccine as rollout..
AQ
08/16Taiwan rejects COVID vaccine candidate, president to get domestic shot
RE
08/16Taiwan denies approval for UBI's COVID-19 vaccine candidate
RE
08/12Medigen Vaccine Biologics Corporation Reports Earnings Results for the Second..
CI
More news
Financials
Sales 2020 11,5 M 0,41 M 0,41 M
Net income 2020 -674 M -24,3 M -24,3 M
Net cash 2020 1 545 M 55,6 M 55,6 M
P/E ratio 2020 -28,6x
Yield 2020 -
Capitalization 60 773 M 2 187 M 2 188 M
EV / Sales 2019 4 269x
EV / Sales 2020 1 755x
Nbr of Employees 103
Free-Float 65,3%
Chart MEDIGEN VACCINE BIOLOGICS CORPORATION
Duration : Period :
Medigen Vaccine Biologics Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDIGEN VACCINE BIOLOGICS CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Managers and Directors
Tsan Chien Chen General Manager & Director
Yu Ping Yang Head-Finance & Accounting
Shih Chung Chang Chairman
Yi Hsu Huang Chief Technology Officer & Deputy General Manager
Ming Cheng Chang Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MEDIGEN VACCINE BIOLOGICS CORPORATION177.67%2 173
CSL LIMITED9.25%102 325
WUXI BIOLOGICS (CAYMAN) INC.19.75%63 410
SAMSUNG BIOLOGICS CO.,LTD.12.95%51 545
BIOGEN INC.22.20%44 664
ALEXION PHARMACEUTICALS, INC.0.00%40 336